207 related articles for article (PubMed ID: 23356032)
41. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR.
Sharma A; Sharma VK; Rajwanshi A; Das A; Kaur I; Kumar B
Lepr Rev; 1999 Sep; 70(3):281-6. PubMed ID: 10603717
[TBL] [Abstract][Full Text] [Related]
42. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy.
Tejasvi T; Khaitan BK; Khanna N; Pandhi RK; Singh MK
Indian J Lepr; 2006; 78(4):329-37. PubMed ID: 17402345
[TBL] [Abstract][Full Text] [Related]
44. Relapses during long-term follow up with drug-susceptible M. leprae among multibacillary leprosy patients treated with multidrug therapy regimens; case reports.
Thomas A; Hari L; Nagarajan M; Prabhakar R
Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):391-4. PubMed ID: 7594922
[TBL] [Abstract][Full Text] [Related]
45. A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design.
Penna GO; Pontes MA; Cruz R; Gonçalves Hde S; Penna ML; Bührer-Sékula S
Mem Inst Oswaldo Cruz; 2012 Dec; 107 Suppl 1():22-7. PubMed ID: 23283449
[TBL] [Abstract][Full Text] [Related]
46. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
[TBL] [Abstract][Full Text] [Related]
47. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
[TBL] [Abstract][Full Text] [Related]
48. Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.
Craig J; MacRae C; Melvin RG; Boggild AK
Am J Trop Med Hyg; 2019 May; 100(5):1145-1148. PubMed ID: 30915953
[TBL] [Abstract][Full Text] [Related]
49. Impairments and Hansen's disease control in Rondônia state, Amazon region of Brazil.
De Oliveira CR; De Alencar Mde J; De Sena Neto SA; Lehman LF; Schreuder PA
Lepr Rev; 2003 Dec; 74(4):337-48. PubMed ID: 14750579
[TBL] [Abstract][Full Text] [Related]
50. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of fixed duration multidrug therapy for the treatment of multibacillary leprosy: A prospective observational study from Northern India.
Singh I; Ahuja M; Lavania M; Pathak VK; Turankar RP; Singh V; Sengupta U; Das L; Kumar A; Saini GB
Indian J Dermatol Venereol Leprol; 2023; 89(2):226-232. PubMed ID: 36331863
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of MDT in multibacillary leprosy.
Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
[TBL] [Abstract][Full Text] [Related]
53. Incidence of nerve damage in leprosy patients treated with MDT.
Solomon S; Kurian N; Ramadas P; Rao PS
Int J Lepr Other Mycobact Dis; 1998 Dec; 66(4):451-6. PubMed ID: 10347565
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness of the retreatment of patients with multibacillary leprosy and episodes of erythema nodosum leprosum and/or persistent neuritis: a single-center experience.
Lastória JC; Almeida TSC; Putinatti MSMA; Padovani CR
An Bras Dermatol; 2018 Mar; 93(2):181-184. PubMed ID: 29723371
[TBL] [Abstract][Full Text] [Related]
55. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
[TBL] [Abstract][Full Text] [Related]
56. [Characteristics of leprosy reactions in paucibacillary and multibacillary individuals attended at two reference centers in Recife, Pernambuco].
Teixeira MA; Silveira VM; França ER
Rev Soc Bras Med Trop; 2010; 43(3):287-92. PubMed ID: 20563498
[TBL] [Abstract][Full Text] [Related]
57. Longitudinal ocular survey of 202 Filipino patients with multi-bacillary (MB) leprosy treated with 2 year WHO-multiple drug therapy.
Ravanes JM; Cellona RV; Balagon M; Abalos RM; Walsh GP; Walsh DS
Southeast Asian J Trop Med Public Health; 2011 Mar; 42(2):323-30. PubMed ID: 21710853
[TBL] [Abstract][Full Text] [Related]
58. Gene expression patterns associated with multidrug therapy in multibacillary leprosy.
Ferreira H; Leal-Calvo T; Mendes MA; Avanzi C; Busso P; Benjak A; Sales AM; Ferreira CP; de Berrêdo-Pinho M; Cole ST; Sarno EN; Moraes MO; Pinheiro RO
Front Cell Infect Microbiol; 2022; 12():917282. PubMed ID: 35937686
[TBL] [Abstract][Full Text] [Related]
59. Childhood leprosy in a tertiary-care hospital in Delhi, India: a reappraisal in the post-elimination era.
Singal A; Sonthalia S; Pandhi D
Lepr Rev; 2011 Sep; 82(3):259-69. PubMed ID: 22125934
[TBL] [Abstract][Full Text] [Related]
60. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.
Gelber RH; Balagon VF; Cellona RV
Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):493-500. PubMed ID: 15755209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
